Immune-Modulating SBRT Plus Anti-PD-L1 May Convert Immune-Cold ER-positive, HER2-negative EBC Into More Inflamed Tumours and Improve Response By Ogkologos - August 3, 2026 3 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the Neo-CheckRay study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Serplulimab Benefit of Adjuvant Chemotherapy in Patients with ctDNA-positive Resected Stage II Colon Cancer FDA Approves Palbociclib with Trastuzumab, With or Without Pertuzumab, and Endocrine Therapy for the Maintenance Treatment of HR-positive, HER2-positive LA/MBC MOST POPULAR The Growths On This Woman’s Lips Are A Sign That She... April 17, 2020 FDA Approves Pembrolizumab with Chemotherapy for HER2-negative Gastric or Gastro-Oesophageal Junction... December 14, 2023 EMA Recommends Extension of Indications for Acalabrutinib to Include the Treatment... April 3, 2025 Trial Results Highlight Changing Lung Cancer Treatment Landscape October 15, 2018 Load more HOT NEWS Risk of Distant Recurrence of ER-Positive Breast Cancer in Premenopausal Women... Cancer Survivors Face High Rates of Housing Insecurity Patients Treated With Chemotherapy and B Cell–Targeting Agents Show Impaired Serological... Epcoritamab Shows a Manageable Safety and Robust Antitumour Activity in Heavily...
